Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Biotechnology

Healthcare
$14.53 +1.71%

+$0.29 today

Market cap
$1.56B
Beta
0.20
P/E (TTM)
27.8
EPS (TTM)
$0.62
52W Low $10.42High $25.32

Volume 1.86M

Average 3.08M

SRPT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Sarepta Therapeutics, Inc.NASDAQ: SRPT

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 83.7%

Gross margin was 83.7% in Q1 FY2026, up 2.1 pp from a year earlier. On a trailing-twelve-month basis it was 62.4%, down 19.4 pp year over year. Over 3 fiscal years it narrowed by 25.1 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
83.7%+73.7 pp QoQ
Last fiscal yearDec 2025
59.9%-23.3 pp YoY
LTMMar 2026
62.4%-19.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.1 pp——
1 year-23.3 pp——
3 years-25.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
59.9%
Year-over-year change
-23.3pp

Gross Margin vs competitors

How SRPT compares with its peers on the latest reported figures

  • SRPT's LTM Mar 2026 gross margin of 62.4% is the 5th highest of the 6 companies compared; the peer median is 82.1%.
  • Its year-over-year change of -19.4 pp is the lowest of 6, against a peer median of -3.9 pp.
  • Over three fiscal years its change of -25.1 pp compares with a peer median of -2.0 pp.
SRPT Competitors Peer median
Gross Margin for SRPT and competitors
Company Period LTM level YoY 3-year change
IONSIonis Pharmaceuticals, Inc.LTM Sep 202698.2% -0.6 pp+0.7 pp
WVEWave Life Sciences Ltd.LTM Mar 202693.8% -4.1 pp-20.7 pp
PTCTPTC Therapeutics, Inc.LTM Jun 202682.1% -14.9 pp+2.2 pp
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202679.7% -3.9 pp-2.0 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 202662.4% -19.4 pp-25.1 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-153.7% +248.0 pp-9.0 pp
DYNDyne Therapeutics, Inc.FY2025— ——
SLDBSolid Biosciences Inc.FY2025— ——
DSGNDesign Therapeutics, Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
Peer median (excluding SRPT) 82.1%-3.9 pp-2.0 pp

Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue701.89M933.01M1.24B1.9B2.2B
Cost of Revenue97.05M139.99M150.34M319.1M881.5M
Gross Profit604.84M793.02M1.09B1.58B1.32B
Gross Margin86.2%85.0%87.9%83.2%59.9%
Research & Development771.18M877.09M877.39M804.52M1.52B
Selling, General & Admin282.66M451.42M481.87M557.87M478.94M
Operating Expenses1.06B1.33B1.36B1.36B1.97B
Depreciation & Amortization38.02M41.86M44.4M37.72M44.52M
EBITDA(317.41M)(594.85M)(453.69M)316.89M(647.97M)
EBITDA Margin-45.2%-63.8%-36.5%16.7%-29.5%
Operating Income(459.71M)(536.2M)(267.82M)218.08M(657.77M)
Operating Margin-65.5%-57.5%-21.5%11.5%-29.9%
Interest Income511K27.72M85.97M71.77M19.57M
Interest Expense63.53M53.25M22.01M18.39M9.73M
Other Income / Expenses40.76M(153.76M)(252.27M)42.69M(44.45M)
Income Before Tax(418.95M)(689.96M)(520.1M)260.77M(702.23M)
Pre-Tax Margin-59.7%-73.9%-41.8%13.7%-31.9%
Income Tax Expense(168K)13.53M15.88M25.54M11.19M
Net Income(418.78M)(703.49M)(535.98M)235.24M(713.41M)
Net Margin-59.7%-75.4%-43.1%12.4%-32.5%
EPS (Basic)(5.15)(8.03)(5.80)2.47(7.13)
EPS (Diluted)(5.15)(8.03)(5.80)2.34(7.13)
Weighted Avg Shares81.26M87.56M92.4M95.08M104.79M
Weighted Avg Shares (Diluted)81.26M87.56M92.4M107.88M104.79M

Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Intrinsic Alpha fair value

Locked

Current Price

$14.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.